Medisinstart is a counseling service in pharmacies where patients who start taking a new medicine receive two follow-up appointments with a pharmacist. The aim of the service is to promote correct medication use and increase patient adherence. The effect of Medisinstart has previously been studied among patients starting a new cardiovascular drug. The aim of the project is to map the effects of Medisinstart among patients starting a new medication for type 2 diabetes. Knowledge about the effects of Medisinstart is important in order to maximize the benefits of the service for patients and society. The project is being conducted as a randomized controlled trial among adult patients starting a new medication for type 2 diabetes. The intervention group receives Medisinstart, while the control group only receives prescription dispensing as normal. Data collection includes HbA1c analysis in blood samples and responses to questionnaires. HbA1c is an established measure of glycemic control.

Inclusion Criteria:

• Extracted a new drug/active substance (A10A/A10B) for type 2 diabetes
• Age ≥ 18 years
• The drugs are administered by the patient/relatives
• Good command of Norwegian, both written and spoken

Exclusion Criteria:

• Inability to understand and/or complete consent forms, questionnaires and/or other patient-oriented materials
• Not able to attend physical appointments in the pharmacy
• Not given written consent to participate in the study
• Diabetes medication is administered by a healthcare professional
• Known pregnancy
• HbA1c is unsuitable as an average measure of blood glucose at baseline
• Received initiation of medication for type 2 diabetes within the last year
• Ongoing participation in other studies involving similar interventions to increase adherence and ensure correct medication use